Invert vs Moderna

Side-by-side comparison of AI visibility scores, market position, and capabilities

Moderna leads in AI visibility (90 vs 40)
Invert logo

Invert

EmergingHealthcare

General

AI bioprocessing data platform for cellular agriculture and synthetic biology optimizing fermentation with 90% data reduction; $20.6M raised at $5M revenue serving industrial biotech scale-up.

AI VisibilityBeta
Overall Score
C40
Category Rank
#383 of 596
AI Consensus
76%
Trend
stable
Per Platform
ChatGPT
34
Perplexity
40
Gemini
45

About

Invert is a San Francisco-based AI software company providing data analytics and process optimization infrastructure for biomanufacturing — enabling bioprocessing teams at cellular agriculture, synthetic biology, and industrial biotech companies to manage, analyze, and optimize their bioprocess data in real-time. Founded and backed with $20.6 million raised, Invert generates $5 million in revenue and employs 40 people, applying meta-learning approaches that reportedly reduce new data requirements for process optimization by up to 90%.

Full profile
Moderna logo

Moderna

LeaderHealthcare Tech

Enterprise

mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.

AI VisibilityBeta
Overall Score
A90
Category Rank
#2 of 596
AI Consensus
83%
Trend
stable
Per Platform
ChatGPT
92
Perplexity
93
Gemini
89

About

Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.

Full profile

AI Visibility Head-to-Head

40
Overall Score
90
#383
Category Rank
#2
76
AI Consensus
83
stable
Trend
stable
34
ChatGPT
92
40
Perplexity
93
45
Gemini
89
40
Claude
96
40
Grok
95

Key Details

Category
General
Enterprise
Tier
Emerging
Leader
Entity Type
brand
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.